Jul. 20 at 4:13 PM
$RPID On the face of it, I love RPID's automation idea. However, after some thought and research following the last presentation with Amgen, I see issues with this type of disruptive technology.
1) RPID's special plates claim to have a longer dessication profile, which for the most part has been countered with the big microbiology companies offering extra-filled agar plates, which takes away from their savings equation.
2) The time to implementation is longer than I expected (in years), giving other automation companies runway to improve microbiology operations with less disruption.
3) Relationships with existing vendors is a large barrier in the microbiology world. (Specifically calling out the inertia within microbiology)
4) What happen's if RPID cannot supply their proprietary plates? Can labs that transition fully to RPID transition back to normal plates and not disrupt plant operations? (Risk)
